Latest filing published 20 Aug 2024 for Acadia Pharmaceuticals INC, €438k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Filings by Stephen Davis span 3 companies, the busiest being Acadia Pharmaceuticals Inc, Bellicum Pharmaceuticals, Inc and Heron Therapeutics, Inc. /DE/. We count 34 filings; the first trade dates from 15 October 2021 and the latest from 19 August 2024.
No open-market purchase appears, only 10 sales worth €4.4M. Outside the open market, there are 5 share grants and 19 option exercises. In 2024 alone, the filings show no purchases and 5 sales.
On 20 August 2024 came the latest disclosure, an open-market sale for €438k in Acadia Pharmaceuticals Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 34 declarations